Rallybio(RLYB) - 2025 Q4 - Annual Report

Clinical Development - The company is advancing RLYB116, a C5 inhibitor, which has completed two Phase 1 clinical trials demonstrating significant tolerability improvements and sustained inhibition of terminal complement[27][28] - RLYB332, a long-acting MTP-2 antibody for treating iron overload diseases, is in preclinical development and aims to address significant unmet needs in patients with severe anemia[31] - RLYB116 has shown significant improvement in tolerability and complete inhibition of terminal complement in Phase 1 clinical trials[50] - RLYB116 levels exceed C5 by a ratio greater than 2:1 within 12 hours of a 300mg dose, administered once weekly[56] - Non-clinical studies of RLYB332 demonstrated favorable tolerability and sustained pharmacodynamic effects, supporting its development[61] Strategic Alliances and Collaborations - The company has entered into a strategic alliance with AbCellera to co-develop up to five rare disease therapeutic targets, focusing on unmet needs in rare metabolic diseases[33] - A strategic alliance with AbCellera aims to discover and commercialize novel antibody-based therapeutics for rare diseases[62] - The company has entered into a Product License Agreement (PLA) with Affibody, granting non-exclusive and exclusive rights for the use of Affibody ligands for human therapeutic use[78] - The company has a collaboration agreement with Johnson & Johnson, which includes an upfront payment of $0.5 million and potential additional payments based on study triggers[98] Financial Aspects and Market Opportunities - Concurrent financing related to the merger includes a commitment of approximately $505.5 million from investors for shares of Candid common stock[19] - The company received $20.0 million from the sale of its interest in the ENPP1 program, including $7.5 million upfront and $12.5 million from a milestone payment[32] - The company estimates over 25,000 cases of immune platelet transfusion refractoriness (PTR) annually in the U.S. and major markets, highlighting a substantial market opportunity[39] - Current treatments for PTR are expensive and challenging, indicating a need for more accessible and effective solutions[40] Merger and Acquisition Details - The merger with Candid is expected to result in pre-Merger equityholders of Candid owning approximately 57.55% of the combined company, while Rallybio's pre-Merger equityholders will own about 3.65%[21] - The proposed merger with Candid could result in a termination fee of $1.425 million and expense reimbursement of up to $500,000 if not completed[210] - Following the merger, existing securityholders of the company are expected to own approximately 3.65% of the combined company, while former Candid securityholders are expected to own approximately 96.35%[213] - The merger is contingent on satisfying specific conditions, and failure to meet these could adversely affect the company's operations and stock price[209] - The company is subject to significant transaction costs related to the merger, regardless of its completion[215] Regulatory Compliance and Approval Processes - Regulatory compliance is critical, as failure to meet FDA requirements may result in delays or refusal of product approvals[105] - The FDA application fee for submitting an NDA or BLA for fiscal year 2025 is approximately $4.3 million, with an annual program fee exceeding $403,000 per program[117] - The FDA conducts a preliminary review of all NDAs and BLAs within 60 days of receipt and informs the sponsor by the 74th day whether the application is sufficiently complete for substantive review[118] - The FDA has ten months to complete its initial review of a standard application and six months for priority review applications, with possible extensions of three additional months[119] - The approval process for an NDA or BLA can result in either an approval letter or a Complete Response Letter (CRL), with the latter outlining deficiencies that must be addressed for reconsideration[123] Market and Pricing Dynamics - The downward pressure on healthcare costs has led to increased barriers for new product entry, with significant scrutiny on pricing and reimbursement levels[193] - Third-party payors in the U.S. are increasingly challenging the price and cost-effectiveness of biopharmaceutical products, leading to uncertainty in coverage and reimbursement[189] - In some foreign countries, drug pricing must be approved before marketing, with requirements varying widely and potentially impacting demand[190] Manufacturing and Production - The company relies on third-party contract manufacturers for the production of product candidates, with no current plans to establish internal manufacturing facilities[100] - The company has enhanced the manufacturing process of RLYB116 to improve tolerability and increase dosage[46] - The FDA requires compliance with cGMP regulations for manufacturing, which includes quality control and assurance measures[137] Employment and Operational Structure - As of December 31, 2025, the company employed 14 full-time employees, with 7 engaged in new product sourcing and 7 in administrative functions[204] - The company is winding down general and administrative operations not needed post-merger while continuing limited R&D to maximize the potential value of contingent value rights (CVRs)[34] Risks and Challenges - The company is at risk of losing key personnel during the merger process, which could impact its operations[212] - The completion of the merger is uncertain, and any material adverse changes could negatively impact the stock price of the combined entity[216] - The company may face fines, product recalls, and operational restrictions if it fails to comply with foreign regulatory requirements[187]